Successful TRPV1 antagonist treatment for cardiac hypertrophy and heart failure in mice
| Autor: | Alexander J. Stokes, Cadie L. Buckley, Jaime S Horton |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Male
medicine.medical_specialty Pyridines Short Communication Biophysics TRPV1 TRPV Cation Channels Apoptosis Cardiomegaly Biochemistry Mice Fibrosis Internal medicine Natriuretic Peptide Brain Animals Humans Medicine Heart Failure Pressure overload business.industry Antagonist Treatment options Matrix metalloproteinase 9 medicine.disease Mice Inbred C57BL Disease Models Animal Matrix Metalloproteinase 9 Pyrazines Cardiac hypertrophy Heart failure Cardiology business |
| Zdroj: | Channels. 7:17-22 |
| ISSN: | 1933-6969 1933-6950 |
| DOI: | 10.4161/chan.23006 |
| Popis: | Heart failure is becoming a global epidemic. It exerts a staggering toll on quality of life, and substantial medical and economic impact. In a pre-clinical model of cardiac hypertrophy and heart failure, we were able to overcome loss of heart function by administering the TRPV1 antagonist BCTC (4-(3-Chloro-2-pyridinyl)-N-[4-(1,1-dimethylethyl)phenyl]-1-piperazinecarboxamide). The results presented here identify TRPV1 antagonists as new treatment options for cardiac hypertrophy and heart failure. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|